News | Antiplatelet and Anticoagulation Therapies | March 21, 2016

Novel Oral Anticoagulants Predicted to Challenge Warfarin in VTE Treatment

GlobalData analyst says NOACs will recover from slow initial uptake due to fast action, elimination of regular coagulation monitoring

NOACs, novel oral anticoagulants, VTE treatment, venous thromboembolism, GlobalData

March 21, 2016 — The use of novel oral anticoagulants (NOACs) will see a substantial rise after an initially sluggish uptake and will start to be elected over warfarin, according to an analyst with research and consulting firm GlobalData. Warfarin is the current standard-of-care product in certain indications. 

Lakshmi Dharmarajan, Ph.D., GlobalData's senior analyst covering cardiovascular and metabolic disorders, stated that: “NOACs are increasingly being used in patients with venous thromboembolism (VTE) due to the drugs’ rapid onset of action and the ability to be administered in fixed doses without the need for regular coagulation monitoring.

“Among the VTE population, the fastest to adopt NOACs have been the orthopedic patient segments, for the prevention of deep vein thrombosis (DVT).”

For those with DVT, Xarelto has been demonstrated by real-world studies to have economic advantages over standard-of-care treatments.

As Dharmarajan explained: “Positive evidence such as shorter hospital stays, in addition to the obvious clinical benefits of these drugs, will encourage payers and healthcare systems to recognize their financial advantages over existing treatments.

“For the anticoagulation market in general, a concerted effort by NOAC manufacturers to provide clinical practice evidence is absolutely essential for these drugs to challenge the 65-year legacy built by warfarin.”

Fortunately for such manufacturers, the launch of reversal agents will help boost NOAC usage in the near future. Even in cost-conscious markets such as the United Kingdom, physicians envision a dramatic shift towards NOACs, at least for the majority of the VTE population.

“For NOAC developers, the next step should be to evaluate the efficacy and safety of the drugs for patients with VTE and cancer, and also for the prophylaxis of VTE. This would enable the treatment to achieve universal acceptance in the VTE population as the standard-of-care therapy,” the analyst concluded.

For more information: www.globaldata.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome
News | Deep Vein Thrombosis| July 07, 2017
BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th...
Sex-Specific Cardiovascular Drug Dosages Needed to Reduce Adverse Reactions in Women
News | Womens Healthcare| July 07, 2017
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper...
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies| June 29, 2017
Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority...
Overlay Init